>PROKKA_00001 Clostridium P-47 protein
MNNLKPFIYYDWGKTILKNTKENYSTNEIIPKTFSMELNGTKITNSTLNGTWKSWNLTDE
GEGSHPVLKCIIDDGYLDMNFGASSEKIPLKNVWIKLCMKINPNSDGTYSIPEKSSSFYI
KDNSLKISKDNLILDKYLNKLMLSYFKNNIKNIEMFINKSRIQTKVVGDLSLLGWNTENS
VSFRTMNEFIKKDNLYPKDFKAVYSYRKMTFTATGTFDSWEMTTGADGRNIRFKCPIKSA
AYDLDGDVFNSSTENFLLIQVDLTYFDSKTTINDPTGENDGKQFNLKVKTNDDKLKNVLI
VTYNLTDTDGSMSSEDKDFLSLAFRNWFNENIQQFEQIFAYILLDETAKIPEYQWLKPTQ
ISYGSASVETANDEPDLDASIFSAMSMVENNTNSTPSHAVDNRMLQLTKTQAAFGISFPL
FIEHFLKQALLSSQFISVDDIVADINTLTITNNKQIIFGKVENSDGKNVDSSLKPGKLKL
SLQNNLIVLELFDLTWEQGRGVTGHFDFRQEYELALEAKSGNQIPILKVHDEPEIEYYVE
EAQWKTNEDMIVSAVVGTVFSMILGASMKLAGSALSKAGKLIRSKATTIKGRKKIYINRS
NVRQLRKDSGVTEIELQRINRRNSSIAAEDARLISNNGTTSIQTLGDMKKKPMSTGQRIA
IGAKKIAGTAVMFGAVGLGMNFGEMLINYINAMENNDYSAIPGINSFMQQCIGAMQWPDK
DSELKVTFGKLQGIYLLGGTLEKNNKPNSK*
>PROKKA_00002 hypothetical protein
MKQTFSFNFDDTLSNSSGLIHLEKVNQNCSPNYQYFKIKFIEGYLHIKNKSGNILEKYDL
KDLISLIALKKDYLKLSPLNNKKPKEFTNMKNKHLENRFNLYIINGDIYKKITKNGFLEE
IILNRLLLSILLGNEENLLQIA*
>PROKKA_00003 hypothetical protein
MLLLKGISLSDYDEWHTDETIIFINSKRHYLWLVIDPESCLIIFYHLSSYRNT*
>PROKKA_00004 RNA polymerase factor sigma-70
MDEVKTIENLFFIIKILKDNNKKFEDIYMNYKNLIDIFIKKYNLSENYNDILNHFWIILI
KADLNKFNTENDLNKYISKCLKRYCLSICMKKNRDKKIIYNSEITDINLNLIQDNCFNDI
EFEFKDLISILPNTQQNIIYMKFFKDMKDIEIAKKLKISRQSVYKNKSLALEKLKPILKE
LINI*
>PROKKA_00005 Clostridium P-47 protein
MNTYGWDIVYGCSKRVVNKHLEDYITKNKVEFLYSNTAKKQEIKMAFDNWEIINGGSSNF
LRIKTPIKEGYFKVKNTTIDLSGVNPVLEIKLDFFNDLSNPNIKKLKFNFGSESNDDIKI
IVSDLNGKLQEEDEFYFNKLLINAFIQNEKQISYIFASLNVTSDIEWMNPKQFKFVYYSP
TDNSAGYLFILSVVTNRDISKLSTNVDGNILGNNSEVGLLISEKLFLQNLALPKLSSNMG
SNITSNNFKVISTSDTTGRIANNSTLNWYGLKVGLIWYYPKINNFSMELFEGNKLKTKLS
GIVRLTGYERIYSELNLECTTKFIYDPKNKKASFEDYKTSIMSCKPIFGWLDGAAALVAK
SVGDWSLKSFRGSLAFGLTNNFTDIINGIVRWNNLKISQVTNVTLNVGFCIQGNAN*
>PROKKA_00006 Tetanus toxin precursor
MKINNNFNIDSPVDNKDVAIVRGRKIDAFFKAFQVAPNIWVAPERYYGESLNINEDQKSD
GGIYDSNFLLTNDEKDEFLQATVKILQRINNNVVGAKLLSLISTAIPFPYEYKPGDYRQT
NYLVSKDNQHYYTANLVIFGPGTNIVENNAVYYKKEDSENGMGTISEIWFQPFLTYKYDQ
FYVDPALELIKCLIKSLYYLYGIKPSDDLSIPCRLRSEFNSLEYSELDMVDFLISGGIEY
KLLDTNPYWFTDNYFIDAPKNFEKYKNDYETKIKNNNDIANSIKLYLEQKFKINAQDIWE
LNLSYFSTEFEIMMPEIFNNALNHYYRKEYYVIDYFKNYNINGFINGQIKTILPLSKYNK
NIINKPELVVNLINEDNAVLMKSNVYGDGLKGTMDNFYAAYKIPYNIGDEYHINYSYLNN
VNVEEINNIPPINDADIYPYRKNSDPFIPVYNITETKEINTTTPFSVNYLQAQVANSNDI
SLSSDFSKVISSKDRSLVYSFLDNTIDYLDSIKYDEPINTDKKYYLWLKDIFRNYSFDMT
ETQEVNTLYGINKVVPWLGKALNILNTGNSFIEEFKSLGPISLINKKENITMPKIEIDEI
PNSMLNLSFKDLSENLFNRFSKNNSYFEKIYYDFLDQWWTQYYSQYFDLICMAKKSILAQ
ESLIKKIIQKKLSYLIGNSNISSDNLALMNLTTTNTLRDISNESQIAMNNVDSFLNSAAI
CVFEGNIYSKFISFMEQCINNINKNTREFIQKCTNITENEKLQLINQNIFSSLDFDFLNI
ENLKSLFSSETALLIKEETSPYELVLYAFQEPDNNAIGDASAKNTSIEYSKDIDLVYGIN
SDALYLNGSNQSISFSNDFFENGLTNSFSIYFWLRNLGKDTIKSKLIGSKEDNCGWEIYF
QDTGLVFNMIDSNGNEKNIYLSDVSNNSWHYITISVDRLKEQLLIFIDDNLVANESIKEI
LNIYSSNIISLLSENNPSYIEGLTILNKPTTSQEVLNNYFKVLNNSYIRDSNEERLEYNK
TYQLYNYVFSDKPICEVKQNNNIYLTINNTNNLNLQLSKFKLLSINSNKQYVQKFDEVII
SILGNMEKYIDISEDNRLQLIDNKNGAKKMIISNDMFISNCLTLSCGGKYICLSMKDENH
NWMIRNNDMSKYLYLWSFK*
>PROKKA_00007 Botulinum neurotoxin type A precursor
MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHDVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAEHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDVASTLNKA
KSIIGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVNFFKV
INRKTYLNFDKAVFRINIVPDENYTIKDGFNLKGANLSTNFNGQNTEINSRNFTRLKNFT
GLFEFYKLLCVRGIIPFKTKSLDEGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLDKVEE
ITADTNIEAAEENISLDLIQQYYLTFDFDNEPENISIENLSSDIIGQLEPMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGDSRIILTNSAEEALLKPNVAYTFFSSKYVKKINKAVEA
FMFLNWAEELVYDFTDETNEVTTMDKIADITIIVPYIGPALNIGNMLSKGEFVEAIIFTG
VVAMLEFIPEYALPVFGTFAIVSYIANKVLTVQTINNALSKRNEKWDEVYKYTVTNWLAK
VNTQIDLIREKMKKALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINSA
MININKFLDQCSVSYLMNSMIPYAVKRLKDFDASVRDVLLKYIYDNRGTLVLQVDRLKDE
VNNTLSADIPFQLSKYVDNKKLLSTFTEYIKNIVNTSILSIVYKKDDLIDLSRYGAKINI
GDRVYYDSIDKNQIKLINLESSTIEVILKNAIVYNSMYENFSTSFWIKIPKYFSKINLNN
EYTIINCIENNSGWKVSLNYGEIIWTLQDNKQNIQRVVFKYSQMVNISDYINRWIFVTIT
NNRLTKSKIYINGRLIDQKPISNLGNIHASNKIMFKLDGCRDPRRYIMIKYFNLFDKELN
EKEIKDLYDSQSNSGILKDFWGNYLQYDKPYYMLNLFDPNKYVDVNNIGIRGYMYLKGPR
GSVVTTNIYLNSTLYEGTKFIIKKYASGNEDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKDDQGIRNKCKMNLQDNNGNDIGFIGFHLYDNIAK
LVASNWYNRQVGKASRTFGCSWEFIPVDDGWGESSL*
>PROKKA_00008 Autolytic lysozyme
VQIDLYEAMESCYSPKYKELILKLKDKLNNLNKVIHFLFYYQRYNYEKNLGGVYMLKGID
ASEHQGEICWKAVKNSGIQFAILRAGYGKNNIDEQFINNANGCTSVGMPFGLYWFSYAYT
EDMARKEAQYCVAQAKKYKISYPICYDLEYDTIRYANNCGVTITKSLATKMVHAFCQEVE
RNGYFAMNYSNQDFLLNKFDSDLLKRYELWYAWYNNSLNRKCGIWQYSENGRVPGIAGVA
VDMNYCYLNMSGAYNTSPNKNTFRGGHYLIRELQQEINSQGLREVVVDGIAGQATINSVP
VCKQGARGGITKVIQQILISIGYPVGSHGADGVFGDSTVTAIKAFQRDCHLVADGIVGKE
TWKALFRNLK*
>PROKKA_00009 hypothetical protein
MKTIKFKIVAGINEGYFHESKNKNRIQIVGV*
>PROKKA_00010 Nucleoside 2-deoxyribosyltransferase
MSKRVFLAAPFKGAIKEKQSIMKEQEKKRIENLILFLEEKGWKVDNAHKREEWGANSMSP
DQCTKLDYDAIKECDLFIAFPGVPVSPGTHIEIGWASAMGKKIILLLAEKEENYAYLIRG
LHTVSNVHYIIYNEEKEYLQKLNLYLDGENNEV*
>PROKKA_00011 Thymidylate synthase
MKFKNFHEAYLKNLNDVYYNPEFINQPRGNVSKERLNYFMILENPRERICYTKSRKTNIV
FNFAEALWYLSGSNDLDYISYYASNMKKYSMDGKTLTGTAYGPKIFSYGYNKINQWNRII
KLFKEDPDTKRGFIEIFDANEDLSLKNIDVSCTIGFQFFIREHKLYMTTFMRANDAYRGI
ISDVFSFTFIQEFLATELNLDIGQYSHQVATTHIYEPDFKLAEKVLCESKSVKKELSFPR
MPKKDNWEDLKIVLQYEKELRKQRIHLTKKDIDELEIDKYWKQIICLFVLYQEIYYGDNL
DYEIYESLEPLYQYLFSNKWNQYF*
>PROKKA_00012 ubiquinone/menaquinone biosynthesis methyltransferase
MESIFLGGDILGTCWKDEEVSKKFNLYNDMLENILGFDYIFQNLKSNESIKKILDFGCGP
GKVAERMAKIKPESQIIAVDQSQNMLDIAMKEHNKENIDYRLIEQNQLKGIEKNSIDCVV
LCFVIINNSDKDRIKTIFQEIFRVLKKGGKFFILDSNPNAAGVEFSTFTNGKSGQAYRLG
DHKKQFLKIPNNKVLILEDYYWPIDFYINNLEAVGFENYKIVEPTIEKINKRDLNAIEKT
YDIKCWGSEKNKPPFIIFDVEK*
>PROKKA_00013 Thiaminase-1 precursor
MHNERSKTMKFKNLFKRSLSLLFSFIMIFTLVSGLNVKAFSGDEPKQTLNVALYEYVPDP
IRFKKAVETEWNKKEPNIKLNFVDWDCYSEDPPKDLDVFVFDAIYLSHFVKKGYLSEIPE
KDIKNKEDILPFAMEGCTIKGSAYAIPQIICTNLLFSRKGDYDIQKVNSVYDLYDKLGKF
TSEDIILPNNKGLLIDMSGGTSKACMYLDSLIDTTQEYTKFCSLPNLNELNKDAIESLVL
LQSMAGKSQANYWPENNDSYIRAKWFINGKGRAYIGYTEAMSQMKEFANDIDFKTISLSK
NSNIPIFYGDVVGINSSITNPYKKEKAIELANIITDKSTMVKAVSPDENNEYPQYLLPAR
RSVYHNLENKYPIYGRLYKIAHNPNNKLFRTGPEIREWLKQAKKIITEYLQQ*
>PROKKA_00014 Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase
MKKVLSIAGSDCSGGAGIQADLKTFSAHGVFGMSVIVSVVAENTSRVIDIQDITPDMIKS
QIDAVYEDIGTDAVKIGMLSTPDCMKAVSEKLQEYKPKNVVIDPVMYAKNGCPLMDPNSV
STLIESIICHADILTPNIPEAERISGYKIKTLEDMEKAAVIIEGMGCKSVLIKGGHYIGD
AVDVLYDGNKFYHYKTQRIHTKNTHGTGCTLSSAIASNLALGFEINEAVKRAKNYITMAI
EHSLEIGKGNGPTNHFYQVYLNGLKGMELDNHTRS*
>PROKKA_00015 hypothetical protein
MRKVYKNPKELATCLKDLVDLYFEDLMTYEKLEEKVSKIVEANKDSIYKNGVINTKLANV
LGNLRIDVINKIVKEEN*
>PROKKA_00016 putative membrane protein
MTKYAIVFFISMVPILELRGAIPYSQAFQLPLLQSYIVAIIGNMLPVPFIYLFARKVLIW
GADKPVIGKFFSWCLAKGEKAGKKLKETAGNKGLFIGLLLFVGIPLPGTGAWTGTLAASF
LDMDFKTSILAVMLGVLVAGIIMGTASVGLFSFF*
>PROKKA_00017 Lipopolysaccharide export system ATP-binding protein LptB
MDKSNDVVVSIRDLKMSYGSKEILKGINLDVNKGEIIGYIGPNGAGKSTTVKIMLGLVKG
YEGEVKIFGNNISYENVEYKHKIGYVPENGEIYDNLTATNI*
>PROKKA_00018 Daunorubicin/doxorubicin resistance ATP-binding protein DrrA
MKLEDVNNKAKKLMSLFGIEEAYHSRISSYSKGMRQKLLIISSLIHNPDILFLDEPLSGL
DANSVLVFKEVLSKLASEGKTIFYSSHIMEVVEKISSRIILLNNGQIAADGTFEELKKKN
MEGSLEQIFNQITGFTKHEEIANEFISVLKEV*
>PROKKA_00019 hypothetical protein
MIKNIMAPIFILIFTIIGDGIKIKTARKTPINPYRSSDFLKVFFLLSFSLSLYIVGTLLL
SIKSFNLSIVLMEA*
